← Back
Data updated: Mar 10, 2026
REGCON HOLDINGS
CardiovascularNeurologyGastroenterology
REGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology. Key products include MOXIFLOXACIN HYDROCHLORIDE.
1999
Since
41
Drugs
-
Trials
376
Approved (2yr)
Recent Activity
PREGABALIN 2026-02-24
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
RIVAROXABAN 2026-02-20
BRIMONIDINE TARTRATE 2026-02-11
Labeling
GLYCOPYRROLATE 2026-02-10
Labeling
GLYCOPYRROLATE 2026-02-06
Labeling
PREGABALIN 2026-02-03
Labeling
PREGABALIN 2026-02-02
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 38%
6 drugs
Neurology 25%
4 drugs
Gastroenterology 13%
2 drugs
Oncology 13%
2 drugs
Ophthalmology 13%
2 drugs
Pipeline Strength Pro
Loading...
Active (25)
RIVAROXABAN LOFEXIDINE HYDROCHLORIDE BRIMONIDINE TARTRATE AND TIMOLOL MALEATE VARENICLINE TARTRATE ELETRIPTAN HYDROBROMIDE SUMATRIPTAN NEOSTIGMINE METHYLSULFATE MOXIFLOXACIN HYDROCHLORIDE RASAGILINE MESYLATE DORZOLAMIDE HYDROCHLORIDE DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE CETIRIZINE HYDROCHLORIDE CARVEDILOL BRIMONIDINE TARTRATE FLECAINIDE ACETATE FAMOTIDINE ENALAPRIL MALEATE SOTALOL HYDROCHLORIDE ACYCLOVIR NADOLOL ACETYLCYSTEINE BACLOFEN AMINOCAPROIC ACID SUCCINYLCHOLINE CHLORIDE THIOTEPA
Discontinued (13)
Company Info
- First Approval
- 1999-01-26
- Latest
- 2026-01-29
- Applications
- 46